Founded in April 2006, Concert Pharmaceuticals is a clinical stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium.

Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with potential for best-in-class efficacy and safety, while greatly reducing R&D risk, time and expense.

The Company has over 100 patent applications for new drug candidates addressing a broad range of therapeutic areas, including HIV/AIDS, renal disease, cardiovascular disease, among others. In 2009, Concert’s first patents were granted by the USPTO.

Milestones
edit

Concert Pharmaceuticals — Concert Pharmaceuticals to land $12M from HIV drug's clinical study (11/9/09)

Posted 11/9/09 at 12:01pm
Concert Pharmaceuticals received $37M in Series C funding. (4/30/08)

Posted 5/25/09 at 10:37pm
Concert Pharmaceuticals added Steve Bernitz as Chief Business Officer.

Posted 5/25/09 at 10:23pm
Concert Pharmaceuticals added Nancy Stuart as COO.

Posted 5/25/09 at 10:23pm
Concert Pharmaceuticals added Roger Tung as President and CEO.

Posted 5/25/09 at 10:23pm
Concert Pharmaceuticals added Robert Silverman as Vice President and General Counsel.

Posted 5/25/09 at 10:23pm
Concert Pharmaceuticals added Robert Zelle as Vice President, Drug Development.

Posted 5/25/09 at 10:23pm